CA2878684A1 - Method of treating hyperglycemic disorders using apolipoprotein aiv - Google Patents

Method of treating hyperglycemic disorders using apolipoprotein aiv Download PDF

Info

Publication number
CA2878684A1
CA2878684A1 CA2878684A CA2878684A CA2878684A1 CA 2878684 A1 CA2878684 A1 CA 2878684A1 CA 2878684 A CA2878684 A CA 2878684A CA 2878684 A CA2878684 A CA 2878684A CA 2878684 A1 CA2878684 A1 CA 2878684A1
Authority
CA
Canada
Prior art keywords
apolipoprotein
protein
biologically active
apoa
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2878684A
Other languages
English (en)
French (fr)
Inventor
Patrick Tso
Fei Wang
Sean Davidson
Stephen Woods
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of CA2878684A1 publication Critical patent/CA2878684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2878684A 2012-07-25 2012-11-21 Method of treating hyperglycemic disorders using apolipoprotein aiv Abandoned CA2878684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675549P 2012-07-25 2012-07-25
US61/675,549 2012-07-25
PCT/US2012/066334 WO2014018079A1 (en) 2012-07-25 2012-11-21 Method of treating hyperglycemic disorders using apoliprotein aiv

Publications (1)

Publication Number Publication Date
CA2878684A1 true CA2878684A1 (en) 2014-01-30

Family

ID=47295208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2878684A Abandoned CA2878684A1 (en) 2012-07-25 2012-11-21 Method of treating hyperglycemic disorders using apolipoprotein aiv

Country Status (5)

Country Link
US (1) US10232019B2 (enExample)
JP (1) JP6033433B2 (enExample)
AU (1) AU2012385960B2 (enExample)
CA (1) CA2878684A1 (enExample)
WO (1) WO2014018079A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US9730980B2 (en) 2012-07-25 2017-08-15 University Of Cincinnati Method of treating type I diabetes using apolipoprotein A-IV

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
PL374126A1 (en) 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
AU2009226246A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103788043B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
ES2620404T3 (es) 2011-01-19 2017-06-28 University Of Cincinnati Apoliproteína AIV como péptido antidiabético
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014011908A1 (en) * 2012-07-11 2014-01-16 Esperion Therapeutics, Inc. Apolipoprotein mixtures
US9730980B2 (en) 2012-07-25 2017-08-15 University Of Cincinnati Method of treating type I diabetes using apolipoprotein A-IV

Also Published As

Publication number Publication date
US10232019B2 (en) 2019-03-19
JP6033433B2 (ja) 2016-11-30
WO2014018079A8 (en) 2015-01-22
WO2014018079A9 (en) 2015-03-12
AU2012385960A1 (en) 2015-02-05
AU2012385960B2 (en) 2017-04-13
JP2015524432A (ja) 2015-08-24
WO2014018079A1 (en) 2014-01-30
US20150182591A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
AU2012366182B2 (en) Method of treating diabetes using non-glycosylated apolipoprotein A-IV
US9266941B2 (en) Apolipoprotein AIV as an antidiabetic peptide
WO2008007818A1 (en) Novel use of aimp1 for controlling glucose level
KR20200024263A (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
CN106892975A (zh) 调节糖代谢的多肽及其用途
US10232019B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
US9730980B2 (en) Method of treating type I diabetes using apolipoprotein A-IV
US20220211810A1 (en) Method of Treatment
WO2018165933A1 (zh) 调节糖代谢的多肽及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170929

FZDE Dead

Effective date: 20181121